The Report on Competition policy, published annually, provides detailed information on the most important policy and legislative initiatives, and on decisions adopted by the European Commission in application of EU competition law during the previous year.
Administrator / Assistant in charge: Marco RISTORI / Karen AGHADJIAN
Since the inception of the Single Market, the EU has prioritized open, rule-based trade and economic stability. Recent global challenges, such as the COVID-19 pandemic and rising geopolitical tensions, underscored vulnerabilities in Europe's economic structure, compelling a strategic response. The EC Communication on the European Economic Security Strategy outlines an approach to ensure resilience against emerging risks and safeguard Europe’s technological and economic interests.
- Composition of the Study Group
- Administrator / Assistant in charge: Sveto TRAJKOVSKI / Elisabete DIAS
The EU-UK Follow-up Committee (Committee) was set up in March 2021 for the purpose of maintaining and strengthening relations between EU and UK civil society organisations, as well as for pursuing any activities contributing to enhancing the relationship between the EU and the UK.
The future Belgian presidency of the Council of the European Union asked the EESC to provide their insights on the rethinking of the internal market in light of the acceleration of the Union’s twin transitions towards a green and digital economy and on crafting a European Industrial Strategy that positions industries as the backbone of Europe's economy.
As committed during the negotiations on the long-term EU budget 2021-2027, the European Commission has on 20 June 2023 completed its proposal for a next generation of own resources. The package includes a new temporary statistical own resource based on company profits. The Commission also proposes to adjust the own resources proposals based on the Emissions Trading System (ETS) and Carbon Border Adjustment Mechanism (CBAM) compared to the original proposals from December 2021.
EESC exploratory opinion NAT/913 - Towards the Common Agricultural Policy (CAP) post-2027: for an agricultural sector that meets economic, social and environmental needs
The Covid 19-pandemic has drawn attention to the role of the pharmaceutical industry and to production, availability and affordability of medicines and medicinal products on the European market.
Dependency on critical ingredients, such as active pharmaceutical ingredients (APIs), became obvious when China and India limited exports. According to current data, up to 80% of APIs used in Europe and about 40% of finished medicines sold in Europe come from China or India. The European Union's increasing dependence on API supplies has led to a partial loss of capability to manufacture active substances independently, which poses a potential threat to public health in the countries of the European Union.